Earlier, prominent occurrences of interstitial loss-of-heterozygosities (LOHs) were found in different cancers as a type of single-nucleotide-variations (SNVs), at rates far exceeding those of the commonly investigated gain-of-heterozygosities (GOHs) type of SNVs. Herein, such co-occurrences of LOHs and GOHs were confirmed in 102 cases of four cancer types analyzed with three different next-generation sequencing platforms, comparing non-tumor, paratumor, and tumor tissues with white-blood-cell controls; and in 246 pan-cancer cases of whole-genome tumor-control pairs.
Introduction
The progressive development of cancer has been investigated at the cytochemical and genetic levels [1] [2] [3] [4] [5] [6] , and the existence of early premalignant stages in the process has been suggested by precancer manifestations in terms of DNA, gene expression, protein and microscopic changes [7] [8] [9] [10] [11] [12] [13] [14] . Genomic analysis has played an increasingly important role toward delineation of mutational events 15, 16 , and a recent study by us has led to the finding of massive single-base interstitial loss-of-heterozygosities (LOHs) in various types of cancers, pointing to widespread intersister chromosomal gene conversions arising from defective DNA double-strand break (DSB) repair in tumor development 17 . Thus the interplay between the gain-of-heterozygosity (GOH) and LOH types of single nucleotide variations (SNVs) requires examination along with copy number variations (CNVs) as mutational elements of cancer regarding the extent of possible reversion of forward mutations during cancer development.
In the present study, non-tumor, paratumor, primary tumor and metastatic tumor tissues in different types of solid tumors were compared with same-patient whiteblood-cell controls based on massive parallel sequencing. Somatic mutations in both directions, i.e. GOHs, LOHs, CNV gains and CNV losses were examined residue-byresidue and window-by-window in order to detect the presence of mutation reversals in the development of cancer cells and to assess their biological significance. The results obtained suggested that forward-reverse cycles of mutations along with directional selection are important determinants of stage-specific cell population profiles in cancer development.
Results

Genotypic changes in non-tumor and paratumor tissues
White-blood-cells (B), tumor tissue (T), paratumor tissue (P) immediately adjacent to tumor, and more remote non-tumor tissue (N) were collected in twelve same-patient tetra-sample cases consisted of four breast carcinomas (BRCA), five stomach adenocarcinomas (STAD) and three hepatocellular carcinomas (LIHC) Table 1) , and subjected to DNA analysis using the AluScan platform based on inter-Alu polymerase chain reaction (PCR) followed by massively parallel sequencing (MPS) as described in Methods. The genotype of a base residue was referred as a major allele (M) when it matched the genotype on human reference genome hg19, or as a minor allele (m) when there was no match, thereby enabling the identification of changes in the form of MM-to-Mm GOH ('GOH-M'), mm-to-Mm 17 .
GOH ('GOH-m'), Mm-to-MM LOH ('LOH-M') or Mm-to-mm LOH ('LOH-m')
Figs. 1a and 1b show the total number of residue-by-residue changes in the N-, P-or T-sample genomes relative to B-sample, viz. ∆NB, ∆PB or ∆TB respectively in terms of GOH-M, GOH-m and LOH (sum of instances of LOH-M and LOH-m). Since the numbers of GOH-M, GOH-m and LOH mutations were higher in DNB than in DTB, and comparable in DPB and DTB, both the N-sample and P-sample cells had to be Table 1) . Notably, a forward-reverse mutation cycle (FR-cycle) was commonly observed in the patch diagrams in Fig. 1b : GOHs were strongly reversed by LOHs (e.g., G1 mutations reversed by L1 mutations), and LOHs strongly reversed by GOHs (e.g., L14 reversed by G12). Moreover, the LOH mutations of Mm residues 6 displayed pronounced lineage effects, favoring the formation of MM residues when the Mm residues themselves were derived from MM residues, but favored the formation of mm residues when the Mm residues were derived from mm residues (as in the LOH mutations highlighted by yellow triangles in the figure).
Notably, in Fig. 1b right panel, partition of germline Mm residues via LOH steps L13
and L14 yielded a greater MM/mm product ratio than partition via LOH steps L15
and L16, and greater still than partition via LOH steps L21 and L22, although in each instance MM products exceeded mm products (Fig. 2a) . Since all these three successive partitions emanated from germline Mm residues, their diminishing MM/mm ratios could not be the consequence of lineage effects. Instead, because MM residues in the genome generally have been optimized for growth by prolonged evolution, they tend to be favored over mm residues. Accordingly, the finding of When the trinucleotide-based mutational profile method 18 was employed to classify the GOHs and LOHs observed in the B-N-T-P tetra samples into the C>A, C>G, C>T, T>A, T>C and T>G groups, the results showed that C>T and T>C mutations were particularly prominent among both GOHs and LOHs, in keeping with the general expectation that transitions exceed transversions in SNVs (Fig. 1d) . The C>T GOHs among the ∆NB changes displayed peak frequencies at the four NCG triplets, conforming to the 'Signature 1A' (marked by four solid arrowheads) common to 7 cancers, and likely ascribable to the contribution of spontaneous deaminations of 5-methyl-cytosine at methylated CpG to form thymidine 18, 19 . These deaminations would also explain the ~50% greater occurrence of C>T GOHs than T>C GOHs in the ∆NB changes. In support of this, Fig. 2b shows that although there were less CG dimers than other dimers among AluScan captured as well as whole-genome sequences (Supplementary Fig. 1 ), more CG dimers underwent SNV mutations than any other dimers. In Fig. 1d , all SNV frequency columns in the ∆NB tier were represented by a When another seventeen B-N-T trio sample sets consisted of one BRCA, two LIHC and fourteen non-small cell lung cancers (NSCLC) were analyzed with respect to 8 GOH and LOH changes in the N-and T-stage cells relative to B-stage cells (Fig. 3) , the results obtained showed the same regularities as the B-N-P-T tetra samples: the Bgenomes displayed much higher LOH (L5, L6) rates and GOH-m (G3, G4) rates than GOH-M (G1, G2) rates, strong lineage effects in LOH-partitions between MM and mm products (highlighted by yellow triangles), and prominent FR-cycles viz. L1 reversing G1, L4 reversing G3, G5 reversing L5, and G6 reversing L6. Mm residues between MM and mm products (highlighted by yellow triangles).
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In Fig. 5a , the relative prominences of ∆TN GOHs, ∆TN LOHs, ∆MT GOHs and 
Evidence from mutational profiles for gene conversions in LOH production
For the ∆TB SNVs of Pilot-63 (Fig. 6a) , the alteration-group plots of mutational profile in Fig. 6c revealed strikingly similar heights for the opposing C>T (blue) and T>C (pink) LOH bars in the right panel, but not for the opposing C>T (blue) and T>C (pink) GOH bars in the left panel, consistent with excess LOHs than GOHs. The context-group plots in Supplementary Fig. 2a show comparable rates for all pairs of opposing LOHs in contrast to the unequal rates for the opposing GOHs. The mutation-rate diagrams in Fig. 6d show the actual rates for all opposing GOH pairs and LOH pairs. These results are summarized in Fig. 6e , where over 61% of the rate ratios of opposing substitutions were greater than two for the GOHs (blue bars), but 100% were between one and two for the LOHs (striped red bars), supporting different underlining mechanisms for GOH and LOH. This divergence of the rate ratios between opposing GOHs and opposing LOHs was in accord with our proposal that the LOHs in cancer cells resulted mainly from DSB repairs through gene conversions 17 . In a DSB at a heterozygous C/T, gene conversion could yield either a C/C or T/T homozygous position at comparable rates, depending on which homologous chromatid bears the DSB. On the other hand, because GOHs depend on point mutations rather than gene conversions, this comparable-rate constraint would not apply to GOHs.
Distances between SNVs and recurrent CNVs
That the N-stage SNVs and CNVs in the B-N-P-T tetra samples both underwent active reversions, and more in P-stage than in T-stage (Fig. 2c) , also pointed to some SNV-CNV relationships in the CNV process merits investigation.
Frequency classes of serial CNV changes
In the B-N-P-T tetra-sample cases, the status of any CNV in the N-, P-and T-stages , while the increased density attained might stem from reduced contact inhibition, and the longer generation times could be the result of excessive deleterious mutations.
The FRMD4A gene 32 was mutated in four BRCA cases and three STAD cases in the twelve tetra-sample cases, and CAGE1 for cancer antigen 1 33 was mutated in BRCA, STAD as well as LIHC samples. SNVs recurrent in four out of twelve cases were detected for sixteen different genes (Fig. 8d) . Based on the GOTERM and INTERPRO databases, pathway enrichment analysis show that SNVs in the B-N-P-T tetra samples were frequent in the cell-adhesion and protein kinase pathways (Fig. 8e) .
It was striking that all of the N-stage mutations in the cadherin N-terminal domain family persisted un-reversely throughout the P-and T-stages, pointing to the importance of this family of cell adhesion molecules at multiple stages of cancer development.
In conclusion, because cancers are driven by mutations, the nature of the mutations in the evolving cancer cells furnishes an appropriate basis for delineating the major stages of carcinogenesis. In the present study, the mutational profiles of the cell 
AluScan sequencing
AluScans of genomic regions flanked by Alu repetitive sequences were obtained by means of inter-Alu PCR as described 17, 37 , employing both Head-type and Tail-type 
WGS and WES raw data
Whole-genome sequencing (WGS) data generated from tumor-blood paired samples and treated as non-tumor, or N-stage, samples in this study.
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SNV calling
For the paired-end sequencing reads generated on the Illumina platform by the For cancer cases with more than two samples from each patient, i.e., the B-N-P-T tetra-sample set of twelve cases, the B-N-T trio-sample set of seventeen cases and the N-T-M trio-sample set of seventy-three cases, the above mentioned calling of SNVs were first performed for each sample of each case in the multiple sample sets. For each of the multiple-sample cases, only nucleotide positions conformed to all the above SNV calling criteria in every samples of the same patient were included in further analysis. Sites not covered in further analysis were arising from either lack of sequencing reads or failure to meet filtering criteria in any one of the samples of the same patient.
Mutational profiles of SNVs
Mutational profiles of SNVs were analyzed following the procedure developed by
Alexandrov et al 18 . For each SNV site, the SomaticSignatures package 42 under R environment was employed to determine its preceding and following bases. The results were unnormalized for the observed trinucleotide frequencies in the human genome. The resulting mutation frequency profiles were illustrated in three different graphical presentations, i.e., the alteration-group plot, context-group plot and mutation-rate diagram. Custom R scripts for drawing the three different presentations are available at GitHub website (https://github.com/hutaobo/ProfilePlots).
CNV calling and identification of recurrent CNVs
From AluScan data, the AluScanCNV software 43 
was employed to call paired CNVs between B-and N-stage (∆NB), between N-and P-stage (∆PN), between P-and Tstage (∆TP), between B-and P-stage (∆PB), as well as between B-and T-stage (∆TB)
samples of the same patient in the B-N-P-T tetra-sample sets of twelve cases, using fixed window sizes ranging from 50-to 500-kb. The ∆NB, ∆PB and ∆TB were arranged sequentially to yield the twenty-six possible serial orders shown in Figs. 7a and 7b. To identify recurrent CNVs, all CNVs found in any sequence window of any of the twelve tetra-sample cases at any stages, including ∆NB, ∆PN and ∆TP, were aggregated. CNVs located in the recently identified Distal Zones 22 were removed 24 from further analysis to reduce background noise introduced by less informative windows in the human genome. Only sequence windows where CNV was detected in six or more of the twelve patients were considered to harbor a recurrent CNV.
Co-localization of CNVT and CpGe/MeMRE
CpGe and MeMRE entries were downloaded from UCSC Genome Browser as CpGe or MeMRE density were removed to avoid error caused by missing data, and the remaining windows were separated into ten groups based on the percentile of CpGe or MeMRE density. Finally, the average CNVT breakpoint densities in the groups were plotted against the percentile CpGe or MeMRE density.
Mutation enrichment in genes and pathways
The results of variant analysis of AluScan data of the twelve tetra-sample cases were uploaded to BioMart of the Ensembl database to generate a list of their gene contents under R environment using the 'biomaRt' R package 44 
Statistical analysis and data visualization
Statistical analyses were performed using R software (http://www.r-project.org). The significance probability (p) values were calculated by the two-tailed t.test or chisq.test 
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